Frontline Tislelizumab Improves Survival in PD-L1+, Advanced Gastric/GEJ cancer
Tislelizumab plus chemotherapy may be a new first-line treatment option for patients with PD-L1-positive, advanced gastric or GEJ cancer.
Diagnosis & Disease Information
HER-Vaxx Improves Survival in HER2+ Advanced Gastric/GEJ Cancer
Adding HER-Vaxx to standard chemotherapy improves survival in patients with HER2-overexpressing, advanced gastric or GEJ cancer, a study suggests.
Frontline Zolbetuximab Plus Chemo May Be New Standard Care for Gastric/GEJ Cancer
Adding zolbetuximab to standard frontline chemotherapy can improve outcomes in certain patients with gastric/GEJ cancer, a phase 3 study suggests.
COVID-Related Delays in Gastrointestinal Cancer Diagnosis Did Not Impact Survival
The COVID-19 pandemic delayed the diagnosis of gastric, esophageal, or GEJ cancer but did not impact survival in a single-center study.
Bemarituzumab Improves OS, Not PFS, in Gastric and GEJ Cancer
Adding bemarituzumab to chemotherapy improved overall survival in FGFR2b-expressing gastric or gastroesophageal junction cancer.
Diverticular Disease Associated With Increased Risk of Multiple Cancers
Patients with diverticular disease had an increased risk of lung, prostate, breast, hematologic, colorectal, gastric, liver, and pancreatic cancers.
Several Factors May Predict Risk of ILD/Pneumonitis After Trastuzumab Deruxtecan
The risk of ILD/pneumonitis was associated with patient age, time since cancer diagnosis, dose of trastuzumab deruxtecan, and other factors.
Laparoscopic Surgery Noninferior for Gastric Cancer at Five Years
At 5 years, OS and RFS rates were similar with laparoscopic surgery and open distal gastrectomy.
Significant County-Level Variability Seen With Gastrointestinal Cancers
Counties in the Southeastern United States primarily accounted for the highest 5% of mortality rates for gastric, pancreatic, and colorectal cancer.
FOLFOX, Nivolumab, Trastuzumab Fares Best in ERBB2-Positive Gastric Cancer
A chemotherapy-containing regimen appears more effective than a chemotherapy-free regimen as first-line therapy for ERBB2-positive gastric cancer.
- Loading...
Loading...
Next post in Gastrointestinal Cancers
Loading... 
Loading...